There is an urgent need to identify biomarkers to guide personalized therapy in castration-resistant prostate cancer (CRPC). We aimed to clinically qualify androgen receptor (AR) gene status measurement in plasma DNA using multiplex droplet digital PCR (ddPCR) in pre- and post-chemotherapy CRPC.
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study / Conteduca, V., Wetterskog, D., Sharabiani, M.T.A., Grande, E., Fernandez Perez, M.P., Jayaram, A., Salvi, S., Castellano, D., Romanel, A., Lolli, C., Casadio, V., Gurioli, G., Amadori, D., Font, A., Vazquez Estevez, S., González Del Alba, A., Mellado, B., Fernandez Calvo, O., Méndez Vidal, M.J., Climent, M.A., et al.. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 2017:(2017). [10.1093/annonc/mdx155]
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study
Romanel, Alessandro;Demichelis, Francesca;
2017-01-01
Abstract
There is an urgent need to identify biomarkers to guide personalized therapy in castration-resistant prostate cancer (CRPC). We aimed to clinically qualify androgen receptor (AR) gene status measurement in plasma DNA using multiplex droplet digital PCR (ddPCR) in pre- and post-chemotherapy CRPC.| File | Dimensione | Formato | |
|---|---|---|---|
|
mdx155.pdf
accesso aperto
Tipologia:
Versione editoriale (Publisher’s layout)
Licenza:
Creative commons
Dimensione
328.16 kB
Formato
Adobe PDF
|
328.16 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione
